U.S. Beverage Stock News

NYSE:CSTM
NYSE:CSTMMetals and Mining

Should Constellium’s Q1 Profit Jump and Completed Buybacks Prompt Action From Constellium (CSTM) Investors?

In the first quarter of 2026, Constellium SE reported higher sales of US$2,461 million and net income of US$199 million, alongside completing a multi-year share repurchase program totaling 14,779,353 shares for US$221.14 million under its February 2024 authorization. This combination of stronger profitability and substantial buybacks has prompted several research firms to upgrade their outlook on Constellium, highlighting improved earnings expectations and a more shareholder-focused capital...
NasdaqGM:CAMT
NasdaqGM:CAMTSemiconductor

Camtek’s AI Orders And Acquisition Drive Lofty Growth Expectations And Valuation

Camtek (NasdaqGM:CAMT) reports exceptionally strong incoming orders tied to advanced semiconductor packaging and AI-driven inspection. The company highlights recent AI-focused deals, including its acquisition of Visual Layer, as a key part of its technology roadmap. Management signals an expectation for more than 25% revenue growth in the second half of 2026, pointing to a step change in demand. For investors tracking NasdaqGM:CAMT, the fresh orders and AI-focused investments add a new...
NasdaqGM:CHRS
NasdaqGM:CHRSBiotechs

Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives

Coherus Oncology (CHRS) opened Q1 2026 with total revenue of US$12.3 million and a basic EPS loss of US$0.27, presenting a clear picture of a business still in investment mode. Over recent quarters the company reported revenue of US$7.7 million in Q4 2024, US$7.6 million in Q1 2025, US$10.3 million in Q2 2025, US$12.7 million in Q4 2025, and US$12.3 million in the latest quarter. Over the same period, basic EPS losses moved from US$0.40 in Q4 2024 to US$0.41 in Q1 2025, then around US$0.38...
NYSEAM:FLYX
NYSEAM:FLYXAirlines

FlyExclusive (FLYX) Q1 Loss Of US$7.9 Million Reinforces Ongoing Profitability Concerns

flyExclusive (FLYX) opened Q1 2026 with total revenue of US$96.4 million and a basic EPS loss of US$0.17, alongside a net income loss of US$7.9 million. These figures put fresh numbers behind a business that is still working through loss-making quarters. The company reported revenue of US$91.4 million in Q4 2024, US$88.1 million in Q1 2025, and US$96.4 million in Q1 2026, while quarterly EPS has remained in loss territory between US$0.17 and US$0.30 over that period. This has kept margins...
NYSE:ACH
NYSE:ACHHealthcare

Accendra Health (ACH) Q1 Loss Narrows Challenging Bearish Profitability Narratives

Accendra Health (ACH) has kicked off Q1 2026 with revenue of US$627.8 million and a reported loss of US$6.5 million, translating to EPS of US$0.08, while trailing twelve month revenue sits at about US$2.7 billion with a loss of US$105.3 million and EPS of US$1.37. Over recent quarters the company has seen revenue move between US$673.9 million in Q1 2025 and US$709.0 million in Q4 2025, alongside EPS shifting from a loss of US$0.05 in Q1 2025 to a loss of US$0.12 in Q4 2025, before the latest...
NYSE:ESNT
NYSE:ESNTDiversified Financial

Is It Time To Reassess Essent Group (ESNT) After Steady Returns And Valuation Gap

Wondering if Essent Group at US$60.87 is still a good deal or already pricing in the story? This article breaks down what the current share price might be implying about value. The stock has been relatively steady, with returns of 1.2% over the past week, 0.6% over the past month, a decline of 5.9% year to date, and a 4.6% return over the last year. The 3 year and 5 year returns sit at 48.5% and 40.5% respectively. Recent coverage around Essent Group has focused on its position within the...
NasdaqGM:OCUL
NasdaqGM:OCULPharmaceuticals

A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Pullback

Recent trading in Ocular Therapeutix (OCUL) has drawn attention, with the stock declining over the past week while remaining higher over the past month and over the past year. See our latest analysis for Ocular Therapeutix. Taking a step back, the stock’s recent pullback sits against a mixed backdrop, with the share price down year to date but a 1 year total shareholder return of 30.86%, suggesting earlier optimism has cooled near the current US$9.16 level. If you are comparing Ocular...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative

Halozyme Therapeutics (HALO) opened 2026 with Q1 revenue of US$376.7 million and basic EPS of US$1.27, against a backdrop where trailing 12 month revenue sits at about US$1.5 billion and EPS at US$2.94. Over recent quarters, the company has seen revenue move from US$298.0 million in Q4 2024 to US$264.9 million in Q1 2025, then to US$325.7 million in Q2 2025, US$354.3 million in Q3 2025, US$451.8 million in Q4 2025, before the latest US$376.7 million print. Quarterly basic EPS has ranged from...
NYSE:PAYC
NYSE:PAYCProfessional Services

Paycom Wrestling Sponsorship Adds New Angle To Valuation And Momentum Story

Paycom Software (NYSE:PAYC) is sponsoring the National Duals Invitational, a new collegiate wrestling event with a $1 million prize pool. The sponsorship links Paycom to a high-profile college sports platform, extending its visibility beyond its payroll and HR software business. This move is intended to deepen community engagement and reach student athletes, fans, and future workforce participants. For investors watching NYSE:PAYC, this sponsorship adds a fresh angle to a story often...
NYSE:TUYA
NYSE:TUYASoftware

Tuya (TUYA) Heads Into Q1 2026 With 18% Net Margin Challenging Bearish Narratives

Tuya (NYSE:TUYA) heads into its Q1 2026 reporting cycle with recent numbers that give investors clear reference points, with Q4 2025 revenue at US$84.5 million and basic EPS of US$0.03 backed by trailing twelve month revenue of US$321.8 million and EPS of US$0.09 versus prior year figures that included smaller profits and an earlier loss. Over the past six quarters, revenue has moved from US$81.6 million in Q3 2024 to US$82.1 million in Q4 2024 and then to US$84.5 million by Q4 2025, while...
NasdaqGS:VINP
NasdaqGS:VINPCapital Markets

Vinci Compass Investments (NasdaqGS:VINP) One Off Gain Lifts EPS And Tests Bullish Narratives

Vinci Compass Investments (NasdaqGS:VINP) opened 2026 with Q1 revenue of R$274.9 million and Basic EPS of R$1.57, set against trailing twelve month revenue of R$1.0 billion and Basic EPS of R$4.13 that sit alongside a net margin of 26% and a 105.4% year over year earnings improvement influenced by a R$96.1 million one off gain. Over the past six reported quarters, revenue has ranged from R$234.7 million in Q1 2025 to R$274.9 million in Q1 2026, while quarterly Basic EPS has moved between...